The chemokine system and its contribution to leukemogenesis and treatment responsiveness in patients with acute myeloid leukemia

Journal of B.U.ON.

Volumn 14, Issue SUPPL.1, 2009, Pages

  Olsnes, A M ^a   Hatfield, K J ^a   Bruserud, Øystein ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute myeloid leukemia; Angiogenesis; Chemokine; T cells; Therapy

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; BORTEZOMIB; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEP 005; PLERIXAFOR; PROTEIN KINASE C ACTIVATOR; REPERTAXIN; SB 220502; SB 22502; STROMAL CELL DERIVED FACTOR 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW CELL; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL DIFFERENTIATION; CELL MIGRATION; CONFERENCE PAPER; CYTOKINE RELEASE; DOWNSTREAM PROCESSING; DRUG EFFECT; HUMAN; HYPOXIA; INFECTIOUS COMPLICATION; LEUKEMOGENESIS; MICROENVIRONMENT; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; STEM CELL MOBILIZATION; STROMA CELL; TREATMENT RESPONSE;

CHEMOKINES; CHEMOKINES, CC; CHEMOKINES, CXC; HUMANS; INTERLEUKIN-8; LEUKEMIA, MYELOID, ACUTE; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES;

EID: 70350042929     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (84)

1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368: 1894-1907.
2. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004; 25: 75-84. (Pubitemid 38167488)
3. Laurence AD. Location, movement and survival: the role of chemokines in haematopoiesis and malignancy. Br J Haematol 2006; 132: 255-267.
4. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastas Rev 2006; 25: 357-371.
5. Bruserud Ø, Ryningen A, Olsnes AM et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007; 92: 332-341.
6. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2002; 2: 123-128.
7. Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. Ann Rev Paharmacol Toxicol 2002; 42: 469-499.
8. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Ann Rev Immunol 2000; 18: 217-242.
9. Murphy PM, Baggiolini M, Charo IF et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52: 145-176.
10. Moser B, Willimann K. Chemokines: role in inflammation and immune surveillance. Ann Rheum Dis 2004; 63 (Suppl 2): ii84-ii89. (Pubitemid 39424666)
11. Lipp RW, Wirnsberger GH, Ratschek M, Stepan V, Holzer H, Leb G. The influence of vascular diathesis on the localization of inflammatory foci in renal allografts with a specific anti-granulocyte antibody. Eur J Nucl Med 1996; 23: 395-400. (Pubitemid 26118325)
12. Muller G, Hopken UE, Stein H, Lipp M. Systemic immunoregulatory and pathogenic functions of homeostatic chemokine receptors. J Leuk Biol 2002; 72: 1-8.
13. Rollins BJ. Inflammatory chemokines in cancer growth and progression. Eur J Cancer 2006; 42: 760-767.
14. Christopherson K, Hromas R. Chemokine regulation of normal and pathologic immune responses. Stem Cells 2001; 19: 388-396. (Pubitemid 32900081)
15. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Ann Rev Immunol 2007; 25: 787-820.
16. Johnson Z, Power CA, Weiss C et al. Chemokine inhibition - why, when, where, which and how? Biochem Soc Transact 2004; 32: 366-377.
17. Mellado M, Rodriguez-Frade JM, Manes S, Martinez AC. Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Ann Rev Immunol 2001; 19: 397-421. (Pubitemid 32368041)
18. Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood 2000; 95: 3032-3043. (Pubitemid 30321151)
19. Comerford I, Nibbs RJ. Post-translational control of chemokines: a role for decoy receptors? Immunol Lett 2005; 96: 163-174.
20. Stetler-Stevenson WG, Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 2001; 11: 143-152.
21. Aref S, Osman E, Mansy S et al. Prognostic relevance of circulating matrix metalloproteinase-2 in acute myeloid leukaemia patients. Hematol Oncol 2007; 25: 121-126. (Pubitemid 47507879)
22. Tanaka, T. Bai Z, Srinoulpraser Y et al. Chemokines in tumor progression and metastasis. Cancer Sci 2005; 96: 317-322.
23. Lebre MC, Burwell T, Vieira PL et al. Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: a role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation. Immunol Cell Biol 2005; 83: 525-535. (Pubitemid 41805755)
24. Mantovani A, Sica A, Sozzani S et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686. (Pubitemid 39457982)
25. McColl SR. Chemokines and dendritic cells: a crucial alliance. Immunol Cell Biol 2002; 80: 489-496.
26. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002; 2: 106-115.
27. Olsnes AM, Ryningen A, Ersvær E, Bruserud Ø. In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22. J Interfer Cytokine Res 2007; 28: 297-310.
28. Graham GJ, McKimmie CS. Chemokine scavenging by D6: a movable feast? Trends Immunol 2006; 27: 381-386.
29. Bokoch GM. Chemoattractant signaling and leukocyte activation. Blood 1995; 86: 1649-1660.
30. Bach TL, Chen QM, Kerr WT et al. Phospholipase c beta is critical for T cell Chemotaxis. J Immunol 2007; 179: 2223-2227.
31. Dekker LV, Segal AW. Perspectives: signal transduction. Signals to move cells. Science 2000; 287: 982-983.
32. Wong M, Fish EN. RANTES and MIP-lalpha activate stats in Tcells. J Biol Chem 1998; 273: 309-314. (Pubitemid 28042210)
33. Ward SG, Bacon K, Westwick J. Chemokines and T lymphocytes: more than an attraction. Immunity 1998; 9: 1-11. (Pubitemid 28361290)
34. Locati M, Torre YM, Galliera E et al. Silent chemoattractant receptors: D6 as a decoy and scavenger receptor for inflammatory CC chemokines. Cytokine Growth Factor Rev 2005; 16: 679-686. (Pubitemid 41505523)
35. Broxmeyer HE. Chemokines in hematopoiesis. Curr Opin Hematol 2008; 15: 49-58.
36. Homey B, Muller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2002; 2: 175-184.
37. Qin S, Rottman JB, Myers P et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101: 746-754. (Pubitemid 28096070)
38. Kim CH. Migration and function of FoxP3+ regulatory T cells in the hematolymphoid system. Exp Hematol 2006; 34: 1033-1040.
39. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem cells 2006; 24: 1030-1041. (Pubitemid 44464736)
40. Cignetti A, Vallario A, Roato I et al. The characterization of chemokine production and chemokine receptor expression reveals possible functional cross-talks in AML blasts with monocytic differentiation. Exp Hematol 2003; 31: 495-503. (Pubitemid 36793956)
41. Jin JO, Park HY, Kim JW et al. Phosphatidic acid induces the differentiation of human acute promyelocytic leukemic cells into dendritic cell-like. J Cell Biochem 2007; 100: 191-203.
42. Balkwill F. Cancer and the chemokine network. Nat Rev 2004; 4: 540-550.
43. Bruserud Ø, Gjertsen BT. New strategies for the treatment of acute myelogenous leukemia: differentiation induction - present use and future possibilities. Stem cells 2000; 18: 157-165.
44. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006; 6: 93-106.
45. Schioppa T, Uranchimeg B, Saccani A et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003; 198: 1391-1402. (Pubitemid 37392484)
46. Mohle R, Bautz F, Rafii S et al. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 1998; 91: 4523-4530. (Pubitemid 28270300)
47. Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004; 104: 550-557.
48. Konoplev S, Rassidakis GZ, Estey E et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer 2007; 109: 1152-1156. (Pubitemid 46435395)
49. Spoo AC, Lubbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007; 109: 786-791. (Pubitemid 46105982)
50. Dommange F, Cartron G, Espanel C et al. CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. FASEB J 2006; 20: 1913-1915. (Pubitemid 44933777)
51. Tobler A, Moser B, Dewald B et al. Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia. Blood 1993; 82: 2517-2525. (Pubitemid 23304277)
52. Strieter RM, Polverini PJ, Kunkel SL et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270: 27348-27357.
53. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001; 12: 375-391.
54. Bruserud Ø, Ryningen A, Wergeland L, Glenjen NI, Gjertsen BT. Osteoblasts increase proliferation and release pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 2004; 89: 391-402.
55. Ryningen A, Wergeland L, Glenjen N, Gjertsen BT, Bruserud Ø. In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic interleukin 8. Leuk Res 2005; 29: 185-196.
56. de Bont ES, Vellenga E, Molema G et al. A possible role for spontaneous interleukin-8 production by acute myeloid leukemic cells in angiogenesis related processes: work in progress. Med Pediatr Oncol 2001; 37: 511-517. (Pubitemid 33101390)
57. Hsu HC, Lee YM, Tsai WH et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology 2002; 63: 64-69.
58. Ostermann H, Rothenburger M, Mesters RM, van de Loo J, Kienast J. Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy. Br J Haematol 1994; 88: 332-337. (Pubitemid 24318182)
59. Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud Ø. Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr Cancer Drug Targ 2005; 5: 229-248.
60. Lee CY, Tien HF, Hu CY, Chou WC, Lin LI. Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia. Br J Cancer 2007; 97: 877-882.
61. Harrison JS, Rameshwar P, Chang V, Bandari P. Oxygen saturation in the bone marrow of healthy volunteers. Blood 2002; 99: 394.
62. Lisy K, Peet DJ. Turn me on: regulating HIF transcriptional activity. Cell Death Differ 2008; 15: 642-649.
63. Cummins EP, Taylor CT. Hypoxia-responsive transcription factors. Pflugers Arch 2005; 450: 363-371.
64. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005; 306: re12.
65. Hirota K, Semenza GL Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 2006; 59: 15-26. (Pubitemid 43903276)
66. Du R, Lu KV, Petritsch C et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13: 206-220. (Pubitemid 351318372)
67. Demock K, Marinaro J, McInnis I et al. Hypoxia-inducible factor-1 (HIF-1) and HIF-2 are independent prognostic factors for normal karyotype acute myeloid leukemia (NK AML). Blood 2008; 112 (Suppl 1): 887.
68. Song LP, Zhang J, Wu SF et al. Hypoxia-inducible factor-1alpha-induced differentiation of myeloid leukemic cells is its transcriptional activity independent. Oncogene 2008; 27: 519-527.
69. Huang Y, Du KM, Xue ZH et al. Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1alpha. Leukemia 2003; 17: 2065-2073. (Pubitemid 37441189)
70. Zhang J, Du KM, Xue ZH et al. Accumulation of hypoxia-inducible factor-1 alpha protein and its role in the differentiation of myeloid leukemic cells induced by all-trans retinoic acid. Haematologica 2008; 93: 1480-1487.
71. Peng ZG, Zhou MY, Huang Y et al. Physical and functional interaction of Runt-related protein 1 with hypoxia-inducible factor-1 alpha. Oncogene 2008; 27: 839-847. (Pubitemid 351186314)
72. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7: 678-689. (Pubitemid 47327397)
73. Olsnes AM, Motorin D, Ryningen A, Zaritskey AY, Bruserud Ø. T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunol Immunother 2006; 55: 830-840.
74. Bruserud Ø, Wendelboe Ø. Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy? Expert Opin Biol Ther 2001; 1: 1005-1016.
75. Olsnes AM, Ersvær E, Ryningen A, Bruserud Ø. Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors. Hematology 2008; 13: 329-332.
76. Olsnes AM, Ersvær E, Ryningen A et al. The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. Br J Haematol 2009 (E-pub ahead of print).
77. Altinoz MA, Korkmaz R. NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer. Neoplasma 2004; 51: 239-247. (Pubitemid 38915539)
78. Gharavi NM, Alva JA, Mouillesseaux KP et al. Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. J Biol Chem 2007; 282: 31460-31468.
79. Johnson Z, Power CA, Weiss C et al. Chemokine inhibition - why, when, where, which and how? Biochem Soc Trans 2004; 32: 366-377.
80. Bizarri C, Pagliei S, Brandolini L et al. Selective inhibition of interleukin-8-induced neutrophil Chemotaxis by ketoprofen isomers. Biochem Pharmacol 2001; 61: 1429-1437. (Pubitemid 32452359)
81. Lee B, Ratajczak J, Doms RW, Gewirtz AM, Ratajczak MZ. Coreceptor/chemokine receptor expression on human hematopoietic cells: biological implications for human immunodeficiency virus-type 1 infection. Blood 1999; 93: 1145-1156. (Pubitemid 29076128)
82. Pelus LM, Fukuda S. Chemokine-mobilized adult stem cells; defining a better hematopoietic graft. Leukemia 2008; 22: 466-473.
83. Liles WC, Broxmeyer HE, Rodger E et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728-2730. (Pubitemid 37248839)
84. Miklos S, Mueller G, Chang Y et al. Preventive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host disease. Int J Hematol 2009; 89: 383-397